Non-Animal Proteins

ProdiGene begins scale-up of aprotinin from plants

Published in Gene Therapy Weekly, August 29th, 2002

ProdiGene, Inc., has begun commercial scale-up of aprotinin, a protease inhibitor used in cardiac surgery, wound healing, and as a component in pharmaceutical manufacturing.

Aprotinin, traditionally extracted from bovine lungs, is currently used therapeutically to reduce the need for blood transfusions in patients undergoing cardiac bypass surgery. ProdiGene holds the patent for exclusive commercial production of aprotinin in all plants.

Aprotinin produced in maize provides an alternative to animal-derived material. ProdiGene's recombinant aprotinin is equivalent to bovine aprotinin but is not limited by the supply of bovine lungs. This is in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-08-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry